References of "Jerusalem, Guy"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailComparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology.
Garnett, Sally Anne; Martin, Miguel; JERUSALEM, Guy ULg et al

in Breast Cancer Research and Treatment (2013), 138(1), 149-55

Comparisons of duration of response (DoR) and duration of clinical benefit (DoCB) within clinical trials are prone to biases. To address these biases, we used new methodology to prospectively analyze ... [more ▼]

Comparisons of duration of response (DoR) and duration of clinical benefit (DoCB) within clinical trials are prone to biases. To address these biases, we used new methodology to prospectively analyze expected DoR and expected DoCB. Objective response rate and clinical benefit rate were calculated for fulvestrant 500 and 250 mg, and used to calculate expected DoR and expected DoCB for each dose group. The ratios for expected DoR and expected DoCB (expected DoR500/expected DoR250 and expected DoCB500/expected DoCB250) were then calculated, thereby allowing statistical comparisons of these endpoints between each arm of the COmparisoN of Faslodex In Recurrent or Metastatic breast cancer (CONFIRM) trial. Expected DoRs for fulvestrant 500 and 250 mg were 3.2 and 3.6 months, respectively. The expected DoR ratio between fulvestrant 500 and 250 mg was not statistically significant (0.89; 95 % CI, 0.48-1.67, P = 0.724). The expected DoCBs for fulvestrant 500 and 250 mg were 9.8 and 7.2 months, respectively. The expected DoCB ratio showed that the expected DoCB for fulvestrant 500 mg was significantly improved compared with the expected DoCB for fulvestrant 250 mg (1.36; 95 % CI, 1.07-1.73, P = 0.013). Analysis of the expected DoR and expected DoCB showed fulvestrant 500 mg significantly increased expected DoCB compared with fulvestrant 250 mg in the CONFIRM trial. [less ▲]

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailFinal analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg
DI LEO, Angelo; JERUSALEM, Guy ULg; PETRUZELKA, Lubos et al

in Cancer Research. Supplement (2012, December 15), 72(24), 1-4

Detailed reference viewed: 14 (7 ULg)
Full Text
Peer Reviewed
See detailThe 2006 Adjuvant Trastuzumab Convention in Belgium: 5 years later
VANDERHAEGEN, J; PARIDAENS, R; PICCART, M et al

Poster (2012, December)

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailPatterns of Clinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe
ANDRE, Fabrice; MARINSEK, Nina; RICCI, Jean-François et al

in Value in Health (2012, November), 15(7), 419

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailCarcinomatose péritonéale d'origine indéterminée
Marchal, Nathalie ULg; GENNIGENS, Christine ULg; JERUSALEM, Guy ULg

in Revue Médicale de Liège (2012), 67(11), 582-586

La carcinomatose péritonéale est définie comme l'envahissement néoplasique secondaire du péritoine. Cette entité peut amener de nombreuses difficultés, à la fois sur le plan de son diagnostic, de sa mise ... [more ▼]

La carcinomatose péritonéale est définie comme l'envahissement néoplasique secondaire du péritoine. Cette entité peut amener de nombreuses difficultés, à la fois sur le plan de son diagnostic, de sa mise au point et de la recherche de son origine ainsi que pour son traitement. Le cas clinique que nous relatons illustre les difficultés pouvant être rencontrées par l'équipe soignante face à une carcinomatose péritonéale et décrit l'importance d'une approche multidisciplinaire pour sa prise en charge. Lorsque son origine n'est pas déterminée avant l'instauration du traitement, la carcinomatose péritonéale entre dans le cadre des carcinomes de primitif inconnu (CAPI). Chez une femme, une telle présentation de CAPI en fait une entité particulière, facteur de meilleur pronostic, pour laquelle un traitement plus spécifique doit être instauré en première intention. [less ▲]

Detailed reference viewed: 27 (2 ULg)
Full Text
Peer Reviewed
See detailPh Ib/II study of BKM120 plus trastuzumab in patients with trastuzumab-resistant HER2+ advanced breast cancer
Pistilli, Barbara; Urruticoechea, Ander; Chan Stephen et al

in Annals of Oncology (2012), 23(supplément 9), 116

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailEuropean inter-institutional impact study of MammaPrint
CUSUMANO, Giuseppe ULg; Generali, D; Ciruelos, E et al

Poster (2012)

Detailed reference viewed: 19 (1 ULg)
Full Text
Peer Reviewed
See detailClinical Management and Resource Utilisation for Postmenopausal Hormone-Receptor-Positive HER2-Negative (HR+ HER2-) Advanced Breast Cancer (BC) in Europe
JERUSALEM, Guy ULg; MARINSEK, Nina; RICCI, Jean-François et al

Poster (2012)

Objective: To understand treatment patterns and quantify resource utilisation of HR+ HER2– Advanced BC, with the overall aim of comparing costs and disease burden as patients progress from hormonal ... [more ▼]

Objective: To understand treatment patterns and quantify resource utilisation of HR+ HER2– Advanced BC, with the overall aim of comparing costs and disease burden as patients progress from hormonal therapy (HT) to chemotherapy (CT). Methods: We conducted a chart audit in France, Germany, The Netherlands, Belgium, and Sweden of 399 living and deceased postmenopausal female patients (target, 75 per country) diagnosed with HR+ HER2– advanced BC in the past 4 years. Patients were required to have progressed on ≥ 1 line of prior HT either in the adjuvant or advanced setting and to have completed ≥ 1 line of CT (minimum 2 full cycles) in the advanced BC setting. The chart audit was completed online using a standardised form developed with the assistance of European academic physicians, pharmacy directors, and hospital administrators. Participation was sought from 25 oncologists per country, except in Germany (15 oncologists and 10 gynecologists to reflect local clinical practice). Study was compliant with European and country market research regulations. Results: Our report details the patient care pathway, CT side effects, and resource utilisation in the inpatient and outpatient settings throughout the continuum of advanced BC care. In the study sample 55% of HR+ HER2– advanced BC patients are first treated with HT and switch to CT after an average of 1.5 lines of HT. This switch is primarily influenced by the extent (56%) and progression rate (36%) of metastases. The switch from HT to CT is associated with increased resource utilisation of treating advanced BC. Conclusions: Our results highlight the increased resource utilisation for postmenopausal HR+ HER2– advanced BC patients treated with CT versus HT. [less ▲]

Detailed reference viewed: 31 (2 ULg)
Full Text
Peer Reviewed
See detailPazopanib (Votrient) dans le traitement du cancer du rein et des sarcomes des tissus mous.
GENNIGENS, Christine ULg; JERUSALEM, Guy ULg

in Revue Médicale de Liège (2012), 67(7-8), 437-42

Renal cell carcinoma accounts for 3% of all malignant tumors. Until a few years ago, immunotherapy (Interferon and/or Interleukin-2) was the only approved systemic treatment in the metastatic setting ... [more ▼]

Renal cell carcinoma accounts for 3% of all malignant tumors. Until a few years ago, immunotherapy (Interferon and/or Interleukin-2) was the only approved systemic treatment in the metastatic setting. Better knowledge of renal cell cancer biology drew attention on the fundamental role of angiogenesis. Several strategies targeting angiogenesis have been developed including VEGF and VEGFR inhibitors. They are now the standard treatment in first and second line. Pazopanib, a VEGFR tyrosine kinase inhibitor, is one of the treatment options recommended for patients with metastatic renal cell carcinoma, in first line and after cytokines failure. Since more recently, pazopanib is also approved in the treatment of metastatic soft tissue sarcoma, after failure of at least one line of chemoterapy. In this paper, we will review the mechanism of action and the clinical results of pazopanib in renal cell carcinoma and sarcoma. [less ▲]

Detailed reference viewed: 34 (2 ULg)
Full Text
Peer Reviewed
See detailLes traitements cibles remplaceront-ils la chimiotherapie?
COLLIGNON, Joëlle ULg; JERUSALEM, Guy ULg

in Revue Médicale de Liège (2012), 67 Spec No

The oncologist dream is to provide more benefit with lower toxicity. The increasing knowledge of molecular mechanism for survival and proliferation of cancer cells leads to the development of targeted ... [more ▼]

The oncologist dream is to provide more benefit with lower toxicity. The increasing knowledge of molecular mechanism for survival and proliferation of cancer cells leads to the development of targeted therapies with impressive results for some cancers even if not associated with chemotherapy. These targeted treatments could be monoclonal antibodies or tyrosine kinase inhibitors. Inactivation of only one oncogene can lead to the regression of tumours as well as the inhibition of only one pathway with one or more inhibitors. This result is related to the oncogenic addiction of these tumours. Examples are imatinib in CML and GIST, trastuzumab in HER2 positive breast cancer, gefitinib in mutated EGFR, crizotinib in EML4-ALK positive lung cancer and, also, vemurafenib in BRAF 600E mutated metastatic melanoma. We shall specifically discuss HER2 positive breast cancer, which represent some 15-20% of breast cancers and the recent targeted and bi-targeted therapies. Trastuzumab, an anti-HER2 monoclonal antibody has changed the prognosis of the disease improving survival in the metastatic and adjuvant setting. Lapatinib, a dual tyrosine kinase inhibitor of EGFR and HER2 is approved with capecitabine in trastuzumab resistant patients and in combination with letrozole in first line. Unfortunately, 20% of patients receiving adjuvant trastuzumab relapse and metastatic patients only transienly respond to trastuzumab or lapatinib combined with chemotherapy. New HER2 targeted drugs are currently in development like pertuzumab, T-DMI or mTOR and PI3K inhibitors. New strategies combining these drugs with or without chemotherapy showed interesting results in metastatic and neoadjuvant trials. The selection of patients who will most benefit from these combinations is still a challenge. Currently, chemotherapy in association with anti-HER2 therapy remains the most effective treatment option. [less ▲]

Detailed reference viewed: 67 (7 ULg)
Full Text
Peer Reviewed
See detailImmediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart, Antonio; Frassoldati, Antonio; Paija, Outi et al

in Clinical Breast Cancer (2012), 12(1), 40-8

BACKGROUND: Letrozole is a proven and effective adjuvant therapy in postmenopausal women with hormone receptor-positive (HR(+)) early breast cancer (EBC). As with other aromatase inhibitors (AIs), long ... [more ▼]

BACKGROUND: Letrozole is a proven and effective adjuvant therapy in postmenopausal women with hormone receptor-positive (HR(+)) early breast cancer (EBC). As with other aromatase inhibitors (AIs), long-term letrozole administration is associated with decreased bone mineral density (BMD) and increased fracture risk. This study compared potential bone-protecting effects of immediate vs. delayed administration of zoledronic acid (ZOL) in patients with EBC receiving adjuvant letrozole. PATIENTS AND METHODS: Patients with HR(+) EBC in whom adjuvant letrozole treatment was initiated (2.5 mg/day for 5 years) were randomized to immediate ZOL treatment (immediate ZOL) or delayed ZOL treatment (delayed ZOL) (both at 4 mg every 6 months). Patients in the delayed ZOL group received ZOL only for a BMD T-score that decreased to < -2.0 (lumbar spine [LS] or total hip [TH]) or for fracture. The primary endpoint was percentage change in the LS BMD at month 12. Patients were stratified by established or recent postmenopausal status, baseline T-scores, and adjuvant chemotherapy history. RESULTS: At 12 months, the LS BMD increased in the immediate ZOL group (+2.72%) but decreased in the delayed ZOL group (-2.71%); the absolute difference between groups was significant (5.43%; P < .0001). Across all subgroups, patients receiving immediate ZOL had significantly increased LS and TH BMD vs. those who received delayed ZOL (P < .0001). Differences in fracture incidence or disease recurrence could not be ascertained because of early data cutoff and low incidence of events. Adverse events were generally mild, transient, and consistent with the known safety profiles of both agents. CONCLUSION: Immediate ZOL administration effectively prevented BMD loss and increased BMD in postmenopausal women with HR(+) EBC receiving adjuvant letrozole, regardless of BMD status at baseline. [less ▲]

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailExtended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial.
Coudert, Bruno; Asselain, Bernard; Campone, Mario et al

in Oncologist (2012), 17(7), 900-909

Purpose. The initial report from the Programme Action Concertee Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the ... [more ▼]

Purpose. The initial report from the Programme Action Concertee Sein (PACS) PACS01 trial demonstrated a benefit at 5 years for disease-free survival (DFS) and overall survival (OS) rates with the sequential administration of docetaxel after FEC100 (fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) for patients with node-positive, operable breast cancer. We evaluate here the impact of this regimen at 8 years. Patients and Methods. Between June 1997 and March 2000, a total of 1,999 patients (age <65) with localized, resectable, non-pretreated, unilateral breast cancer were randomly assigned to receive either standard FEC100 for 6 cycles or 3 cycles of FEC100 followed by 3 cycles of 100 mg/m(2) docetaxel (FEC-D), both given every 21 days. Radiotherapy was mandatory after conservative surgery and tamoxifen was given for 5 years to hormone receptor (HR)-positive patients. Five-year DFS was the trial's main endpoint. Updated 8-year survival data are presented. Results. With a median follow-up of 92.8 months, 639 patients experienced at least one event. A total number of 383 deaths were registered. Eight-year DFS rates were 65.8% with FEC alone and 70.2% with FEC-D. OS rates at 8 years were 78% with FEC alone and 83.2% with FEC-D. Cox regression analysis adjusted for age and number of positive nodes showed a 15% reduction in the relative risk of relapse and a 25% reduction in the relative risk of death in favor of FEC-D. Significant relative risk reductions were observed in the HR-positive, HER2-positive, and Ki67 >/=20% subpopulations. Conclusion. Benefits for DFS and OS rates with the sequential FEC-D regimen are fully confirmed at 8 years. [less ▲]

Detailed reference viewed: 48 (2 ULg)
Full Text
Peer Reviewed
See detailPhase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Jerusalem, Guy ULg; Fasolo, Angelica; Dieras, Véronique et al

in Breast Cancer Research and Treatment (2011), 125(2), 447-455

Detailed reference viewed: 68 (18 ULg)
Full Text
Peer Reviewed
See detailFinal results of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients (Pts) with pretreated metastatic breast cancer (MBC) demonstrating significant antitumor activity
Garcia, A; Awada, A; Chan, S et al

in Journal of Clinical Oncology (2011), 29(supplement 27),

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailTrabectedine (ET-743/Yondelis) dans le traitement des sarcomes des tissus mous et du cancer de l'ovaire.
GENNIGENS, Christine ULg; Jerusalem, Guy ULg

in Revue Médicale de Liège (2011), 66(7-8), 452-5

Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has ... [more ▼]

Soft tissue sarcomas account for 1% of all malignant tumours. Until a few years ago, doxorubicine and ifosfamide were the only active chemotherapy drugs in the metastatic setting. Recently, a new drug has proven its efficacy after failure of standard treatments: the trabectedin; its activity is based on interference with ADN repair mechanisms. Trabectedin has just been also validated and reimbursed in patients with ovarian cancer, in partially sensitive recurrence. In this paper, we will review the mechanism of action and the clinical results of trabectedin. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailA propos d'un cas de rechute tardive de cancer du sein après traitement adjuvant
LOUSBERG, Laurence; SOMJA, Joan ULg; COLLIGNON, Joëlle ULg et al

in Revue Médicale de Liège (2011), 66(5-6), 306-310

Detailed reference viewed: 71 (5 ULg)
Full Text
Peer Reviewed
See detailEditorial. Le cancer du sein.
JERUSALEM, Guy ULg; SCHEEN, André ULg

in Revue Médicale de Liège (2011), 66(5-6), 225-228

Detailed reference viewed: 19 (8 ULg)
Full Text
Peer Reviewed
See detail18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers
Withofs, Nadia ULg; Grayet, Benjamin ULg; Tancredi, Tino ULg et al

in Nuclear Medicine Communications (2011), 32(3), 168-176

Detailed reference viewed: 59 (23 ULg)